PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancer

Shinichi Sakamoto ¹, Kodai Sato ², Takahiro Kimura ³

¹Department of Urology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan. rbatbat1@chiba-u.jp.
²Department of Urology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.
³Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
⁴Department of Urology, National Cancer Center Japan, Tokyo, Japan.
⁵Department of Urology, Shizuoka General Hospital, Shizuoka, Japan.
⁶Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan.
⁷Division of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine, Kobe, Japan.
⁸Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.
⁹Department of Urology, The Jikei University School of Medicine, Kashiwa Hospital, Kashiwa, Japan.
¹⁰Department of Urology, Hokkaido University Faculty of Medicine, Sapporo, Japan.
¹¹Department of Urology, Faculty of Medicine, Kagawa University, Takamatsu, Japan.
¹²Department of Urology, Niigata Cancer Center Hospital, Niigata, Japan.
¹³Department of Urology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
¹⁴Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
¹⁵Department of Urology, Ibaraki Prefectural Central Hospital, Ibaraki Cancer Center, Kasama, Japan.
¹⁶Department of Urology, University of Fukui, Fukui, Japan.
¹⁷Department of Urology, Kurume University School of Medicine, Kurume, Japan.
¹⁸Department of Urology, Teikyo University School of Medicine, Tokyo, Japan.
¹⁹Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
²⁰Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu, Japan.
²¹Department of Urology, University of Tsukuba, Tsukuba, Japan.
²²Department of Urology, Faculty of Medicine, University of Toyama, Toyama, Japan.
²³Department of Artificial Intelligence Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.

⁰Department of Urology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan. rbatbat1@chiba-u.jp.

Scientific Reports +

|

July 3, 2024

View abstract on PubMed

Summary

The optimal prostate-specific antigen doubling time (PSADT) cutoff for Japanese nonmetastatic castration-resistant prostate cancer (nmCRPC) is 4.65 months. Shorter PSADT independently predicts poorer overall survival and cancer-specific survival in nmCRPC patients.

Area Of Science

Urology
Oncology
Medical Statistics

Background

Nonmetastatic castration-resistant prostate cancer (nmCRPC) requires prognostic markers for treatment guidance.
Prostate-specific antigen doubling time (PSADT) is a key indicator of disease progression.

Purpose Of The Study

To determine the optimal prostate-specific antigen doubling time (PSADT) cutoff value correlating with prognosis in Japanese patients with nonmetastatic castration-resistant prostate cancer (nmCRPC).

Main Methods

A multicenter study included 450 Japanese nmCRPC patients.
Survival tree analysis was employed to identify the optimal PSADT cutoff.
Prognostic values were assessed for progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS).

Main Results

The median PSADT at diagnosis was 5.2 months.
Novel hormonal therapy (NHT) significantly improved PFS and PFS2 compared to vintage nonsteroidal antiandrogen agents.
A PSADT cutoff of 4.65 months was identified as the most prognostic.
PSADT < 4.65 months was an independent predictor of poorer OS and CSS.

Conclusions

The optimal PSADT cutoff for predicting prognosis in Japanese nmCRPC patients is 4.65 months.
A PSADT less than 4.65 months is a significant independent prognostic factor for adverse outcomes in nmCRPC.

Keywords:

NHT PSA doubling time Prostate cancer Vintage nmCRPC

Related Concept Videos

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...